Background. Recent studies suggest that surgical lymph node (LN) evaluation may be omitted in select elderly breast cancer patients as it may not influence adjuvant therapy decisions. To evaluate differences in adjuvant therapy receipt and overall survival (OS), we compared clinically node-negative (cN0) elderly patients who did and did not undergo axillary surgery. Methods. Patients aged C70 years in the National Cancer Database (2004-2014) with cT1-3, cN0 breast cancer were divided into two cohorts-those with surgical LN evaluation (one or more nodes removed) and those without (no nodes removed). Propensity scores were used to match patients based on age, year of diagnosis, tumor grade, cT stage, estrogen receptor status, and Charlson-Deyo comorbidity score. A Cox proportional hazards model was used to estimate the effect of LN surgery on OS.
nodal surgery: 46.5%; p \ 0.001). After adjustment for known covariates, patients who did not undergo nodal surgery had a worse OS (hazard ratio 1.66, 95% confidence interval 1.61-1.70). Conclusions. For elderly cN0 breast cancer patients, axillary surgery was associated with higher rates of adjuvant therapy and improved OS. A selective approach to omitting nodal surgery should be considered in elderly patients with cN0 breast cancer as axillary staging may influence subsequent treatment decisions and long-term outcomes.
In 2016, the Society of Surgical Oncology Choosing Wisely Guidelines recommended against routine sentinel lymph node biopsy (SLNB) in women over the age of 70 years with clinically node-negative (cN0), hormone receptor-positive (HR?), invasive breast cancer. This was based on studies evaluating recurrence and overall survival (OS) in a subset of elderly patients when axillary surgery was excluded. 1, 2 While less morbid than an axillary lymph node (LN) dissection, SLNB is still associated with a risk of sensory nerve injury and lymphedema. 3, 4 To mitigate these risks, omitting surgical procedures that do not impact adjuvant management decisions or survival is encouraged. However, the decision to omit SLNB is often made based on the physician's assessment of a patient's overall health, and, in elderly patients with competing comorbidities, this assessment is especially important and potentially challenging.
In 2012, the International Society of Geriatric Oncology and European Society of Breast Cancer Specialists updated their recommendations regarding elderly breast cancer patients to include comprehensive geriatric assessment. 5 In this functionally heterogeneous group, clinical management should be guided by numerous factors other than chronological age alone. However, in a study evaluating guideline-concordant care among elderly breast cancer patients, increased age was associated with decreased guideline compliance, even after adjustment. 6 Prior studies also demonstrate that older women are treated less aggressively, which may contribute to previously observed age-related disparities in breast cancer-specific survival (BCSS). 7, 8 Others have suggested that foregoing axillary staging in older women may compromise oncologic outcomes, and that adjuvant treatment decisions based on LN evaluation may impact OS. 9, 10 However, these findings may be related to selection bias, with healthier patients being more likely to undergo axillary nodal evaluation. For those with competing comorbidities, axillary staging may provide little benefit due to predetermined omission of adjuvant chemotherapy or radiation, regardless of LN results. In light of these competing findings, we aimed to evaluate the potential differences in receipt of adjuvant therapy and the subsequent impact on OS in cN0 elderly breast cancer patients using propensity score matching to compare patients who did and did not receive axillary surgery.
METHODS
Patients C70 years of age diagnosed with cT1-3/cN0 breast cancer from 2004 to 2014 were selected from the National Cancer Database (NCDB). 11 Patients with missing or unknown grade, estrogen receptor (ER) status, number of LNs removed, surgery type, Charlson-Deyo comorbidity score, or survival data were excluded from this study, as were patients with metastatic disease, those who underwent neoadjuvant treatment (chemotherapy, radiation therapy, or endocrine therapy), those who underwent a breast surgery other than lumpectomy or mastectomy, and those with \3 months of follow-up. Patients who did not undergo axillary surgery but had pathologically positive nodes (pN1-3) were also excluded (although not specifically indicated in the NCDB, these may have been diagnosed via core needle biopsy or fine-needle aspiration). Per NCDB reporting requirements, survival information for patients diagnosed in the most recent year (2014) was not included; thus, all patients diagnosed in 2014 were excluded from the analyses (electronic supplementary Fig. 1 ) Study groups were defined as those who underwent surgical LN evaluation (one or more LNs removed) and those who did not (no LNs removed). Patients were matched based on year of diagnosis (within 2 years), tumor grade, clinical T stage, age (within 5 years), ER status, and Charlson-Deyo comorbidity score using a GREEDY method. 12 This method first randomly selects a patient in the untreated group (those who did not undergo LN surgery) and then selects a patient in the treated group who has the closest propensity score to the first patient. Differences between study groups were tested using the Cochran-Mantel-Haenszel test or the stratified Wilcoxon rank-sum (Van Elteren) test, as appropriate. 13 Differences in treatment by LN surgery and pN stage were compared using Chi-square tests.
OS was defined as the time from diagnosis to death, or was censored at the date of last follow-up. Unadjusted median OS and 5-and 10-year survival rates were estimated using the Kaplan-Meier method. Differences between study groups were tested using the log-rank test. A Cox proportional hazards model was used to estimate the effect of LN surgery on OS after adjustment for known covariates. This included a robust sandwich covariance estimator to account for the correlation of patients treated at the same hospital, and accounted for matched sets of patients using stratification. A sensitivity analysis of patients diagnosed from 2010 to 2013 was conducted to ensure that the results were maintained after adjustment for human epidermal growth factor receptor 2 (HER) status, which is only reliably coded in the NCDB from 2010 onward. Similar to the population studied in the Cancer and Leukemia Group B (CALGB) 9343 trial, which compared lumpectomy plus tamoxifen with or without radiation, 2 a subgroup analysis was conducted for cT1/cN0/cM0, grade 1/2, ER? patients.
No adjustments were made for multiple comparisons. Only patients with complete data for all covariates in a given model were included in each analysis. All analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC, USA) and R version 3.3.2 (The R Project for Statistical Computing, Vienna, Austria). Due to the use of de-identified data, our Institutional Review Board granted the study 'exempt' status.
RESULTS

Patient, Tumor, and Treatment Characteristics
Overall, 133,778 matched patients met the inclusion criteria (electronic supplementary Fig. 1 ); 23.6% (n = 31,531) did not undergo LN surgery. Median followup was 56.8 months (95% confidence interval [CI] 56.4-57). Median age was 80 years (IQR 76-84), and 76.3% of patients had a comorbidity score of 0 (Table 1) .
79.9% of tumors were grade 1/2, 89.2% were ER?, and median tumor size was 1.4 cm (IQR 0.9-2.1) ( Table 2 ). In order to maintain the largest possible sample size, each patient who did not have nodal surgery was matched to at least one but up to four patients who had nodal surgery. To achieve this, each untreated patient was first matched to one treated patient, and then the process was repeated up to four times to balance both groups of patients (electronic supplementary Table 1 ).
Nodal surgery was associated with higher rates of all adjuvant treatments for patients with pN1-3 (chemotherapy, 2%; radiation, 49.7%; endocrine, 72%) and pN0 disease (chemotherapy, 5.8%; radiation, 47.5%; endocrine, 58.5%). Patients without nodal surgery had the lowest rates of adjuvant therapy (chemotherapy, 2.8%; radiation, 26%; endocrine, 46.5%; all values p \ 0.001) ( Table 2 ). In cN0, pN0, and pN1-3 patients, the duration of radiation was 43, 44, and 46 days, respectively (p \ 0.001). ( Fig. 1) . Of all node-positive patients (pN1-3), there was a survival benefit for patients who underwent chemotherapy, radiation, and/or endocrine therapy (electronic supplementary Table 2 ). After adjustment, patients who did not undergo nodal surgery had a worse OS (hazard ratio 1.66, 95% CI 1.61-1.70) ( Table 3 ). Factors associated with improved OS included receipt of chemotherapy (hazard ratio 0.86, 95% CI 0.81-0.91), radiation (hazard ratio 0.70, 95% CI 0.68-0.72), and endocrine therapy (hazard ratio 0.75, 95% CI 0.73-0.78). The sensitivity analysis of patients diagnosed from 2010 to 2013 resulted in similar associations (electronic supplementary Table 3 ). After adjustment for covariates, including HER2 status, patients who did not undergo nodal surgery still had a worse OS (hazard ratio 1.59, 95% CI 1.51-1.67).
In the subgroup analysis of patients with cT1, grade 1/2, ER? disease, the unadjusted median OS was significantly higher for patients undergoing nodal surgery compared with those not undergoing nodal surgery (121.5 months vs. 85.7 months, log-rank p \ 0.001; data not shown). When stratified by LN surgery receipt and pN status, the unadjusted median OS remained higher for those who underwent axillary surgery (cN0[pN0: 122.3 months, vs. cN0[pN1-3: 109.9 months, vs. cN0-no nodal surgery: 85.7 months; log-rank p \ 0.001) [electronic supplementary Fig. 3] . When stratified by receipt of endocrine therapy, the unadjusted median OS was also significantly higher for all patients undergoing nodal surgery compared with those not undergoing nodal surgery (nodal surgery ? endocrine therapy: 128.2 months; nodal surgery ? no endocrine therapy: 109.2 months; no nodal surgery ? endocrine therapy: 93.6 months; no nodal surgery ? no endocrine therapy: 76.3 months; log-rank p \ 0.001) (Fig. 2) .
DISCUSSION
The risk of breast cancer increases with age, and over 40% of all breast cancers are diagnosed in women aged C65 years.
14 Several studies have evaluated the utility of SLNB in elderly patients. [15] [16] [17] [18] [19] Based on these studies, the Choosing Wisely Guidelines recommended omission of SLNB in select elderly patients (aged C70 years) with early-stage, cN0, HR? breast cancer as results from axillary staging may not impact subsequent treatment decisions.
In contrast, we demonstrated that 22.2% of node-positive patients undergoing nodal surgery received chemotherapy, compared with 5.8% of those who underwent nodal surgery but were node-negative, suggesting that nodal surgery may still be important for some adjuvant therapy decisions. Similarly, higher rates of endocrine therapy receipt were noted for pN1-3 patients than for those who underwent nodal surgery but were pN0. Although chemotherapy and endocrine therapy decisions appeared to be associated with the SLNB results, receipt of radiation was not as rates of radiation receipt were similar for those who were pN0 and pN1-3. While the specific type of chemotherapy administered may influence outcomes, the NCDB does not delineate between chemotherapy regimens and dosing. However, our data demonstrated that differences in duration of radiation based on surgical axillary staging were not clinically meaningful (difference of 2 days). Regardless of the treatments received, undergoing surgical nodal evaluation remained significantly associated with an improved OS, even after adjusting for known covariates, likely suggesting additional unmeasured variables.
However, OS may not parallel BCSS in elderly patients specifically. In a study of NCDB and Surveillance, Epidemiology, and End Results (SEER) populations, improved BCSS and OS were observed in elderly patients who underwent LN evaluation, compared with those who did not. 10 These findings suggest that many patients tolerate standard management strategies, similar to their younger counterparts, which may prolong survival. However, the authors also comment that patient selection and other unaccounted variables almost certainly affected survival outcomes. To address the issue of patient selection bias, we used propensity score matching to compare outcomes of Groups were propensity matched based on year of diagnosis (within 2 years), grade, clinical T stage, age (within 5 years), ER status, and Charlson-Deyo comorbidity score HR hazard ratio, CI confidence interval, PR progesterone receptor, ER estrogen receptor elderly breast cancer patients who did and did not undergo surgical nodal evaluation, and the results were similar overall.
Others have attempted to identify low-risk elderly populations that may benefit least from axillary nodal evaluation. Welsh et al. demonstrated that utilizing 'lowrisk criteria' for HR? elderly breast cancer patients, which included grade 1, cT1mi-T1c (B2.0 cm), or grade 2, cT1mi-T1b (B1.0 cm), yielded a pN? rate that was nearly one-third of that observed in those who did not meet the criteria (7.8% vs. 22.8%). 9 Similarly, we also demonstrated that surgical nodal evaluation was associated with improved OS for patients with early-stage (cT1/cN0/cM0), grade 1/2, ER? breast cancer, suggesting that even select low-risk patients may benefit from standard axillary staging.
Routine omission of axillary staging based on age and tumor subtype alone has the potential to lead to undertreatment of elderly breast cancer patients. In an analysis of stage I breast cancer patients in the SEER database, older patients were less likely to receive standard of care (radiation and LN sampling), which was associated with improved OS and BCSS rates when received. 20 Comparably, we also noted lower rates of radiation receipt than would be expected for those undergoing breast-conserving surgery (25.2-46.1%), while radiation therapy was associated with improved survival, even after adjustment. Therefore, our findings confirm that some elderly breast cancer patients may indeed be undertreated, and this may vary by region. In our univariate analysis, the Northeast region had the highest rates of omission of axillary surgery compared with other regions across the US, at 30.4%. In the adjusted analysis, facility location in the Northeast was not associated with survival (hazard ratio 0.97, 95% CI 0.93-1.01, p = 0.13); however, this observed trend may be related to the presence of several tertiary care centers in the Northeast, and elderly patients with complex management questions may be referred to cancer centers in this area.
For otherwise healthy older women, a diagnosis of breast cancer may be the leading threat to their survival. In addition to stratification by tumor type, treatment risk stratification among elderly patients by comorbidities is essential to mitigating risks and complications of treatments. Although it is clear for elderly patients with limited survival from competing comorbidities that omission of SLNB is reasonable, our study demonstrated that the majority of patients (94.5%) were classified as having a comorbidity score of 0 or 1. As such, it is particularly important to balance the risk of overtreatment against the potential benefit of adjuvant therapy (based on SLNB results). Our data suggest that physicians may already be choosing wisely and surgically staging patients whom they consider clinically fit to tolerate surgery and adjuvant treatments, and they are avoiding surgery in those patients likely to die from other causes.
Furthermore, there is a growing body of evidence regarding the integration of geriatric care into the multidisciplinary oncology setting to ensure appropriate surgical and adjuvant treatment. 5 In the study by Okonji et al., elderly patients with stages I-III breast cancer underwent Comprehensive Geriatric Assessment (CGA) to determine 'fitness' for treatment. 21 While all 'fit' women aged C70 years underwent primary surgery, only 51% of those with high-risk disease received adjuvant chemotherapy, suggesting potential undertreatment in this population. 21 Interestingly, we found that among patients who underwent LN surgery, those with pN0 disease still had higher rates of adjuvant treatments compared with those without nodal surgery: chemotherapy (5.8% vs. 2.8%), radiation (47.5% vs. 26.0%), and endocrine therapy (58.5% vs. 46.5%). These findings suggest that the SLNB results are not the only drivers of adjuvant therapy decisions. Such variation in practice highlights the importance of geriatric assessment and consensus in a multidisciplinary setting for elderly patients with breast cancer. 5 We suggest a selective approach to surgical LN evaluation that includes a geriatric assessment using validated scales weighed against the risk of local recurrence or distant disease in a multidisciplinary setting. In addition, the use of tumor genomic analyses, such as Oncotype Dx, may help delineate patients at high risk for recurrence, and assist clinicians in patient selection. There were several limitations to our study that need to be acknowledged, including those inherent to large database analyses, such as variations in data entry and coding. Although most patients with no LNs removed likely had no axillary surgery, it is possible that some attempts at sentinel node identification were unsuccessful (e.g. dye/tracer did not map to the axilla, etc.). In addition, the NCDB does not provide BCSS, and OS may not reflect BCSS in elderly breast cancer patients. However, OS is often used as the primary outcome measure in elderly patients to evaluate efficacy of breast cancer treatments in the context of competing comorbidities. We also had limited data on Oncotype Dx Recurrence Scores, and it is possible that some adjuvant treatment decisions were based on Oncotype scores in select HR? patients that obviated the need for axillary nodal evaluation. Although we attempted to minimize patient selection bias (by using the propensity matching for our analysis), it is likely that additional unmeasured variables contributed to our findings to an unknown degree. Furthermore, patients who were selected to undergo axillary surgery may have also been more likely to undergo other treatments (treatment bias).
CONCLUSIONS
In clinically node-negative breast cancer patients C70 years of age, positive nodes were identified in 14% of those undergoing axillary surgery, and treatment patterns in this population were highly variable, which may be reflective of the lack of clear guidelines and/or patient heterogeneity. Regardless, it should not be routinely assumed that the results from an SLNB will not alter treatment decisions. In an overall healthy elderly population, surgical axillary staging was associated with higher rates of adjuvant therapy and improved OS, demonstrating that it remains an important component of surgical therapy. A selective approach to the omission of nodal surgery should be considered in elderly patients with node-negative breast cancer as the surgical outcome may influence subsequent treatment decisions and long-term outcomes. Future studies should evaluate whether similar findings may be reflected in BCSS rates.
